Document 0798
 DOCN  M9440798
 TI    Spectral effects in activation of the human immunodeficiency virus
       promoter by psoralens plus ultraviolet A treatment.
 DT    9404
 AU    Miller SA; Beer JZ; Strickland AG; Zmudzka BZ; Center for Devices and
       Radiological Health, US Food and Drug; Administration, Rockville, MD
       20857.
 SO    Photodermatol Photoimmunol Photomed. 1992-93 Dec;9(6):262-7. Unique
       Identifier : AIDSLINE MED/94128579
 AB    The effects of PUVA treatment on HIV promoter activation and cell
       killing in HIV cat/HeLa cells were studied using two UV sources, a
       UVASUN sunlamp and a UVAR Photoactivation Chamber. A 4 to 5 times higher
       dose of ultraviolet radiation was required from the UVASUN lamp than
       from the UVAR lamps: 1) to activate the HIV promoter in the presence of
       0.1 or 1.0 microgram/ml 8-MOP and 2) to reduce cell survival to a level
       of 10%, in the presence of 0.1 or 1.0 microgram/ml 8-MOP. In addition,
       exposures performed with a fixed dose of 20 kJ/m2 at varying
       concentrations of 8-MOP, required a 4.7 times higher combined PUVA dose
       from the UVASUN lamp than from the UVAR lamps. Two possible sources of
       these differences were analyzed: (1) the presence of UVB + UVA2 (280-340
       nm) in the radiation emitted by the UVAR, but not the UVASUN lamp, and
       its potential biological activity independent of 8-MOP, and (2) the
       difference in the overlap of the emission spectra of the two lamps with
       the absorption spectrum of 8-MOP. The area of overlap was higher for the
       UVAR lamp than for the UVASUN lamp by a factor of 4.6, which is close to
       the difference between these two lamps in induction of the HIV promoter
       and killing HeLa cells. This indicates that the effectiveness of a
       particular UVA source used in combination with 8-MOP can be predicted by
       its congruence to the absorption spectrum of the photosensitizing drug.
 DE    Cell Survival/DRUG EFFECTS/RADIATION EFFECTS  Chloramphenicol
       Acetyltransferase/ANALYSIS  Hela Cells  Human  HIV/DRUG
       EFFECTS/*GENETICS/RADIATION EFFECTS  Methoxsalen/*PHARMACOLOGY  Promoter
       Regions (Genetics)/*DRUG EFFECTS/*RADIATION EFFECTS  PUVA Therapy
       Radiation Dosage  Support, U.S. Gov't, Non-P.H.S.  Support, U.S. Gov't,
       P.H.S.  *Ultraviolet Rays  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).